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Chronic kidney disease (CKD) affects approximately 13% of the U.S. population and is associated with increased
risk of cardiovascular complications. Once renal replacement therapy became available, it became apparent
that the mode of death of patients with advanced CKD was more likely than not related to cardiovascular com-
promise. Further observation revealed that such compromise was related to myocardial disease (related to hy-
pertension, stiff vessels, coronary heart disease, or uremic toxins). Early on, the excess of cardiovascular events
was attributed to accelerated atherosclerosis, inadequate control of blood pressure, lipids, or inflammatory cyto-
kines, or perhaps poor glycemia control. In more recent times, outcome research has given us further informa-
tion that relates even lesser degrees of renal compromise to an excess of cardiovascular events in the general
population and in those with already present atherosclerotic disease. As renal function deteriorates, certain
physiologic changes occur (perhaps due to hemodynamic, inflammatory, or metabolic changes) that decrease
oxygen-carrying capacity of the blood by virtue of anemia, make blood vessels stiffer by altering collagen or
through medial calcinosis, raise the blood pressure, increase shearing stresses, or alter the constituents of ath-
erosclerotic plaque or the balance of thrombogenesis and thrombolysis. At further levels of renal dysfunction,
tangible metabolic perturbations are recognized as requiring specific therapy to reduce complications (such as
for anemia and hyperparathyroidism), although outcome research to support some of our current guidelines is
sorely lacking. Understanding the process by which renal dysfunction alters the prognosis of cardiac disease
might lead to further methods of treatment. This review will outline the relationship of CKD to coronary heart
disease with respect to the current understanding of the traditional and nontraditional risk factors, the role of
various imaging modalities, and the impact of coronary revascularization on outcome. (J Am Coll Cardiol
2009;53:2129–40) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.047t
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the increasing prevalence of chronic kidney disease (CKD)
s staggering. Current estimates from the U.S. show that
3% of the population has CKD, with 341,000 on chronic
ialysis and 140,000 with kidney transplants (1–3).§ This
pidemic is a direct result of the rising tide of the major
auses of CKD, namely, diabetes mellitus (DM) and
ypertension (4). Diabetes mellitus has long been recog-
ized as a risk factor for coronary heart disease (CHD)
vents, but emerging evidence suggests that intensive
lood sugar control in patients with type 1 and 2 DM
esults in delayed reductions of CHD events long after
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1
ohe cessation of intervention, perhaps by slowing the
rogression of CKD (5–7).
Recent studies suggest that CKD is associated with
ncreased risk of cardiovascular (CV) morbidity and mor-
ality in a manner independent of DM (8,9). This associa-
ion is even more evident in patients with end-stage renal
isease (ESRD), where CV mortality accounts for 45% of
ll-cause mortality (2). Sudden cardiac death constitutes
2% of the CV mortality in ESRD or a full one-fourth of
ll-cause mortality (Fig. 1) (10,11). According to another
stimate, the annual rate of sudden cardiac death of an
SRD patient receiving dialysis is approximately 7% (11).
lthough the exact proportion of CKD patients that suc-
umb to sudden death secondary to CHD is unknown, the
According to the National Kidney Foundation guidelines, CKD is defined according
o the presence or absence of kidney damage and level of kidney function as assessed
y the glomerular filtration rate (GFR) (in ml/min/1.73 m2) into 5 stages; stages 1
nd 2 are characterized by kidney damage (structural or functional abnormalities such
s proteinuria) with normal or elevated GFR (90 in stage 1) or mildly decreased (60
o 89 in stage 2), or by decreased GFR irrespective of kidney damage (GFR 30 to 59,
5 to 29, and 15 or dialysis for stages 3 to 5, respectively). In this review, measured
r estimated GFR and creatinine clearance will be designated by GFR for clarity (3).
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Coronary Heart Disease in Chronic Kidney Disease June 9, 2009:2129–40major contributors to this elevated
risk of sudden death are CHD,
myocardial structural changes,
electrolyte imbalance, and auto-
nomic dysfunction (11). CKD is
known to affect cardiac structure
and function. By the time pa-
tients reach ESRD, left ven-
tricular hypertrophy (LVH) is
almost universal and left ventric-
ular (LV) mass has been corre-
lated with survival in this patient
population. ESRD also results in
cardiac fibrosis and in LV sys-
tolic and diastolic dysfunction,
all of which could be related to
the increased incidence of sud-
den death (12). One of the con-
sequences of decreased glo-
merular filtration rate (GFR) is
increased calcification of both
the coronary and the systemic
arteries. These could cause coro-
nary artery narrowing but, also of
importance, decreased compliance
of the aorta and the resultant in-
crease in cardiac afterload (12).
espite this, many if not most CV trials have systematically
xcluded CKD patients, thus potentially limiting some bene-
cial therapies from this high-risk population (13). The inter-
ction between the heart and the kidneys is complex and has
een reviewed recently in the Journal (14); we will outline here
he relationship of CKD to CHD with respect to the current
nderstanding of the risk factors, imaging modalities, and
oronary revascularization.
HD Risk Factors
t is now generally accepted that CKD patients are at high
isk for CV events. Estimates from several trials indicate
hat CV disease accounts for more than 50% to 60% of all
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CHD  coronary heart
disease
CKD  chronic kidney
disease
CRP  C-reactive protein
CV  cardiovascular
DM  diabetes mellitus
EF  ejection fraction
ESRD  end-stage renal
disease
GFR  glomerular filtration
rate
LV  left ventricular
LVH  left ventricular
hypertrophy
MI  myocardial infarction
MPI  myocardial perfusion
imaging
PCI  percutaneous
coronary intervention
RT  renal transplantation
4%
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Figure 1 The Distribution of the Causes of Death in Patients W
Cardiovascular disease accounts for 45% of all-cause mortality, including 26% from
myocardial infarction refers to death that was labeled secondary to acute myocard
those labeled cardiac arrest or cardiac arrhythmias.eaths in patients with CKD before ESRD; most patients
ith CKD succumb to CV death before developing ESRD
3). Both the mortality and the CV events increase with
ecreasing GFR below 60 ml/min/1.73 m2 (adjusted hazard
atio: 1.2, 1.8, 3.2, and 5.9 for death and 1.4, 2.0, 2.8, and
.4 for CV events for GFR categories 45 to 59, 30 to 44, 15
o 29, and 15 ml/min/1.73 m2, respectively) (8). Less
ppreciated is that the mortality of patients with CKD is
igher than the general population after incident myocardial
nfarction (MI) and after undergoing percutaneous coronary
ntervention (PCI), coronary artery bypass grafting (CABG), or
ven insertion of an implantable cardiac-defibrillator (Fig. 2)
10,15–17). Therefore, current guidelines consider patients
ith CKD to be CHD risk equivalent for risk factor
anagement (18). Although almost all traditional risk
actors (advanced age, male sex, DM, hypertension, dyslip-
demia, tobacco consumption, obesity, sedentary lifestyle,
nd family history of CHD) show increased prevalence in
atients with CKD, there has been doubt over their con-
ribution to risk in this population due to the phenomenon
f reverse epidemiology (19). Data from the U.S. Renal
ata System in ESRD patients show that overall and CV
ortality increase sharply for systolic blood pressures lower
han 110 mm Hg but are relatively flat afterward (20).
imilarly, mortality is higher in patients with lower choles-
erol levels irrespective of the use of lipid-lowering medica-
ions (21). The reason for this paradox is now thought to be
he prevalence of disease (at least pre-clinical disease) at
aseline, which seems to affect the risk factor distribution
19). It is now generally accepted that this reverse associa-
ion is most likely secondary to confounding factors,
hereby patients with ESRD who are predisposed to worse
utcome are already malnourished and have higher levels of
ystemic inflammation, and therefore are underweight and
ave low cholesterol level and hypotension (22). It is
mplied then that these risk factors continue to be patho-
hysiologically important and should be addressed aggres-
ively in patients with CKD. Recent lipid-lowering trials
hat included patients with CKD have demonstrated that
ntensive lipid-lowering with statin medications was safe
Myocardial Infarction
Sudden Cardiac Death
Cerebrovascular Disease
Other Cardiovascular 
Infection
Malignancy
Withdrawal from dialysis
Other
nd-Stage Renal Disease in the U.S. Between 2003 and 2005
en cardiac death. Data are from the U.S. Renal Data System (10). In the figure,
rction or atherosclerotic heart disease, whereas sudden cardiac death refers to4%
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June 9, 2009:2129–40 Coronary Heart Disease in Chronic Kidney Diseasend perhaps even more effective in patients with CKD than
n the general population (23). The management of dyslip-
demia and hypertension in CKD have been recently re-
iewed elsewhere and will not be addressed further here, but
uffice it to say that early and aggressive control of these risk
actors is of paramount importance in improving outcomes
24,25). However, because these traditional risk factors fail
o fully account for the elevated CV risk in CKD, there has
een a great deal of interest lately in emerging risk factors
hat are unique to this population (inflammation and
-reactive protein [CRP], oxidative stress, nitric oxide
vailability, hyperhomocysteinemia, hyperphosphatemia,
ascular calcification, increased vascular stiffness, LVH,
nemia, endothelial dysfunction, volume overload and elec-
rolyte imbalance, and timing of dialysis) (26), in the hope
hat modulation of these factors might improve outcomes in
KD patients (Fig. 3).
ystemic inflammation. Atherosclerosis is now considered
n inflammatory condition (27). Serum levels of CRP, the
rototypical acute phase reactant, have been shown to
orrelate well with the future development of CHD events
n the general population (28). Levels of CRP have been
hown to be particularly high when renal function declines
o the level of ESRD, where as many as one-third to
ne-half of the patients have levels in the very-high-risk
ategory, and CRP continues to be an excellent predictor of
utcome in this population (29). A recent prospective study
ollowed a cohort of more than 1,000 ESRD patients for a
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Figure 2 Mortality Is Increased in CKD
Patients After MI, PCI, and CABG
The 2-year mortality of Medicare patients (age 66 or older on the day of the
event or treatment) after receiving first percutaneous coronary intervention
(PCI) or coronary artery bypass graft surgery (CABG) or after incident myocardial
infarction (MI) between the years 2000 and 2005 is higher in chronic kidney
disease (CKD) patients than non-CKD patients. The mortality of end-stage renal
disease (ESRD) patients hospitalized for MI reaches 73% to 74% at 2 years.
This figure is based on data from the U.S. Renal Data System. USRDS 2008
Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Dis-
ease in the U.S. Bethesda, MD: National Institutes of Health, National Institute
of Diabetes and Digestive and Kidney Diseases, 2008.edian of 2.5 years and reported that the highest (compared pith lowest) tertile of CRP was associated with a 2-fold
ncreased adjusted risk of sudden cardiac death (30). In this
tudy, malnutrition (decreased serum albumin) was also
ssociated with sudden death, but the traditional Framing-
am risk factors were not (30). The pathogenesis of the
xtreme elevation of CRP, which is as much as 10-fold
igher in ESRD than in the normal population, is not
ompletely understood; but several explanations have been
roposed, including some that are directly related to the
ialysis procedure itself and others that are linked to uremia,
erhaps via increased oxidative stress (31). More recently,
RP has been shown to be elevated in patients with CKD
t pre-dialysis stages (32) and that it is a powerful predictor
f CV events in this population (33). The major stimulus for
ncreased CRP release by the liver is interleukin-6, which
an be produced by the intra-abdominal adipocytes, and
hus the association between obesity and increased inflam-
ation in CKD (34). The pathogenic nature of CRP is
ighly controversial, with a lack of clinical studies showing
direct cause-and-effect relationship and the failure of
ecent genetic studies to demonstrate a deleterious effect of
RP polymorphisms (35) but strong in vitro and animal
ata that suggest its direct involvement in the vascular
isease process (36). Nonspecific inhibitors of inflammation
ike aspirin and statin medications are possible therapeutic
ptions, and it seems prudent to avoid preventable causes of
nflammation in ESRD patients by using ultra-pure dialysis
uid and more biocompatible dialysis membranes and
inimizing infections of access sites in hemodialysis pa-
ients and peritonitis in peritoneal dialysis patients, but
ore specific therapies are currently unavailable (37).
Because inflammation is at the core of the CHD com-
lications of CKD, it is prudent to recognize its inter-
elation with the other risk factors discussed here, because
athophysiologically it could be related to any or all of them.
or example, CRP levels have been shown to be indepen-
ently associated with anemia (38). Inflammatory mediators
nhibit erythrocyte maturation, and inflammation results in
he increased production in the liver of hepcidin, a factor
hat regulates the uptake of dietary iron and its mobilization
rom hepatic stores (39). Inflammation is also intimately
inked to vascular calcification in patients with CKD (40).
urthermore, there is evidence that CRP might be related
o progression of CKD, thereby closing the loop between
nflammation, CKD, and atherosclerosis (41).
KD mineral and bone disorder. CKD patients have
lterations in their calcium and phosphorus homeostasis
hat ultimately result in bone disorders and soft tissue and
ascular calcifications, a constellation of findings that has
een dubbed CKD mineral and bone disorder (42). The
ntricate mechanisms that regulate these processes and their
elation to renal function have been reviewed elsewhere
43). As a result of renal dysfunction, hyperphosphatemia
obilizes calcium from bone through the action of para-
hyroid hormone. In CKD, the chronic stimulation of the
arathyroid gland results in its enlargement, and it ulti-
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Coronary Heart Disease in Chronic Kidney Disease June 9, 2009:2129–40ately becomes independent from calcium levels (43). This
ituation is further exaggerated by the high prevalence of
utritional vitamin D deficiency in patients with CKD, thus
esulting in an independent stimulus for increasing parathy-
oid hormone (44).
In 1998, Block et al. (45) analyzed national data from 2
arge cohorts that included more than 6,000 ESRD patients
nd found that mortality risk rose sharply when the phos-
horus level increased above 6.5 mg/dl. They further re-
orted that, when the calcium-phosphorus product in-
reased beyond 72 mg2/dl2, the risk of death increased by
4% as compared with the reference range of 42 to 52
g2/dl2. Since then, higher phosphorus and calcium-
hosphorus product have been more specifically linked to
HD and sudden cardiac deaths (46). Also, quantification
f coronary artery calcification with electron-beam com-
uted tomography revealed a direct association with the
revalence of CHD, MI, and angina (47), and the extent of
therosclerotic calcification by ultrasound was strongly as-
ociated with all-cause and CV mortality (48). Perhaps even
ore significantly, in ESRD, coronary artery calcification is
lmost universal even in the second decade of life, and it
rogresses quickly over time (49). This rapid progression
as also been demonstrated in CKD patients not yet
equiring dialysis (50).
The current understanding of atherosclerotic calcification
n CKD is that it parallels bone mineralization and occurs in
Diabetes Mellitus
Coronary H
Ev
Neurohormonal
Activation Homocysteine
Myocardial 
Ischemia / Scar
Genetic Factors
Figure 3 The Association Between Chronic Kidney Disease and
The relationship between chronic kidney disease and cardiovascular events is com
Factors section. “Other risk factors” refers to several risk factors that are not dire
in patients with chronic kidney disease. CRP  C-reactive protein; LVH  left venthighly regulated fashion that can be modulated at multiple mevels. In the uremic milieu vascular smooth muscle cells are
ransformed into osteoblast-like cells that express phospho-
us transporter Pit-1 and lay down an extracellular matrix
apable of concentrating calcium and phosphorus, thereby
llowing crystal nucleation to occur and subsequently full
ineralization. From there, the progression of mineraliza-
ion depends on the balance of pro-calcific factors such as
he calcium-phosphorus product, parathyroid hormone, and
one morphogenetic protein-2 and inhibitory factors such
s the protein fetuin-A, pyrophosphate, osteopontin, osteo-
rotegerin, and -carboxyglutamic acid protein (42,51,52).
t is important to note that some of these factors have
ascular effects that are distinct from their function in bone.
or example, knockout mice for osteoprotegerin develop
ascular calcification accompanied by severe osteoporosis
51). Also, because fetuin-A is a negative acute phase
eactant, its levels drop with inflammation and it is inversely
elated to CRP, providing a link between inflammation and
ascular calcification (51). Other important factors in the
enal regulation of phosphorus that are thought to play
mportant roles in vascular calcification include the bone-
erived fibroblast growth factor-23 and a protein that is
equired for the conversion of its renal receptor, klotho (52).
Although patients with CKD have atherosclerotic calci-
cations in the vessel intima, they also have calcifications
hat involve the vascular media. This pattern of calcification
Monckeberg’s sclerosis) has also been demonstrated to be a
R
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June 9, 2009:2129–40 Coronary Heart Disease in Chronic Kidney DiseaseKD (42). Atherosclerotic calcification is associated with
ncreased vascular stiffness of large capacitive elastic arteries,
hich contributes to the development and progression of
ypertension and LVH. Increasing stiffness of the aorta, as
easured by pulse-wave velocity, has been shown to be an
ndependent predictor of CV mortality in this population
53). Even a simple assessment of vascular stiffness, such as
ulse pressure, showed a strong association with mortal-
ty in a large cohort of more than 30,000 patients with
SRD (12% increase in 1-year mortality for every 10-mm
g increase in pulse pressure) (54). In this study,
lthough patients with lower systolic blood pressure had
orse outcome, increasing pulse pressure within each
ategory of blood pressure was associated with higher
ortality (54).
Understanding the pathophysiology of vascular calcifica-
ions and its risk factors helps in its prevention and in
alting its progression. Current clinical guidelines stress the
mportance of maintaining phosphorus and parathyroid
ormones between strict levels and the use of non–calcium-
ontaining phosphate binders (55). Controlling serum
hosphorus levels in ESRD usually requires dietary phos-
horus restriction, adequate dialysis, and the use of phos-
hate binders. Calcium-containing phosphate binders, such
s calcium carbonate and calcium acetate, are adequate in
ontrolling the serum phosphorus levels but—due to the
igh calcium load that they provide (especially with calcium
arbonate)—increase the calcium-phosphorus product and
timulate vascular calcification (49).
Despite the apparent detrimental effect of vascular calci-
cation in the CKD population, modulation of this process
as been daunting. Because of the differences in calcium
oad, the studies with calcium carbonate should probably be
nalyzed separately from those with calcium acetate. The
xperience with noncalcium-containing phosphorus binders
as produced conflicting results, and more studies are still
eeded (Online Table 1). Furthermore, although initial data
uggested that sevelamer could slow atherosclerosis calcifi-
ation by lowering low-density lipoprotein cholesterol, a
ecent analysis by McCullough et al. (42) demonstrated that
ow-density lipoprotein cholesterol reductions in random-
zed trials of statins and sevelamer did not influence the rate
f progression of atherosclerotic calcification. There is some
vidence that administration of vitamin D to suppress
xcessively elevated parathyroid hormone levels might be
eneficial. Similarly, other treatments such as calcimimetics,
isphosphonates, and newer noncalcium-containing phos-
horus binders (lanthanum carbonate) have been contem-
lated as potential treatments for vascular calcification (52).
yperhomocysteinemia. Almost all patients with ESRD
re known to have moderately elevated homocysteine levels
ue to the decrease in its metabolism by the kidneys. In 1
nalysis, elevated homocysteine and fibrinogen levels were
ble to explain almost 40% of the attributable mortality risk
rom CKD, and subjects with CKD and homocysteine
evels 10 mol/l had mortality rates similar to those with aormal renal function (56). Multiple studies have examined
he potential beneficial effect of lowering homocysteine
evels with folate and vitamin B combinations, but only a
ew included patients with CKD (Online Table 2). The
otality of evidence points to a strong association of plasma
omocysteine with CV outcomes in the general population
s well as in the ESRD population after adjustments for
onfounding factors. Trials that lowered homocysteine by
dministering folic acid and/or B vitamins have largely been
nsuccessful in decreasing coronary events, although their
ffects on strokes is evident in some trials. In the U.S.,
nriched grain products have been fortified with folic acid
ince 1998, mainly because folic acid has been shown to
educe the incidence of neural tube defects in newborns,
hich resulted in a drop by 10% to 15% in the homocysteine
oncentration in the entire population (57). It has been
uggested that this might have resulted in the decreased
ncidence of strokes (58).
nemia. The prevalence of anemia increases with decreas-
ng GFR (59). The pathogenesis of anemia in this setting is
ultifactorial, in part related to iron deficiency and hemo-
ysis but mostly the result of relative erythropoietin defi-
iency (60). Anemia has been associated with increased
ortality, MI, and coronary revascularization (61,62), but
rythropoietin deficiency might also signal a reduction in
one marrow-derived endothelial progenitor cells, and
herefore anemia might be a marker of decreased vascular
epair in patients with CKD (63). Early trials have sug-
ested that erythropoietin treatment might stimulate the
roliferation of these progenitor cells in humans, and
ngoing randomized trials are investigating the benefit of
rythropoietin administration after MI (64,65). It is partic-
larly interesting that, in the large cohort of more than
7,000 individuals of the National Kidney Foundation’s
idney Early Evaluation Program, anemia and GFR were
ndependently associated with CV disease and survival (66).
Erythropoietin and its derivatives were first administered
n patients with ESRD as a means of reducing packed red
ell transfusions, but with the advent of observational
tudies suggesting improved outcomes, their use was liber-
lized to include patients with higher GFR, and hemoglo-
in targets were raised to normal values instead of the more
onservative partial correction of anemia. This approach has
eceived several setbacks from randomized studies over the
ast years. Besarab et al. (67) randomized ESRD patients
ith CHD or heart failure to erythropoietin injections to
chieve and maintain hematocrit levels of either 42% (nor-
al hematocrit) or 30% (conventional treatment). After a
ollow-up of 29 months, the study was stopped early due to
oncerns about safety. The primary end point of death or
onfatal MI was not different between the 2 groups, but
here was a strong trend toward harm in the higher
ematocrit group (relative risk: 1.3, 95% confidence interval:
.9 to 1.9) (67). It is interesting to note that mortality rates
ecreased with increasing hematocrit levels in both groups,
lthough it was higher for patients in the “normal hemat-
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Coronary Heart Disease in Chronic Kidney Disease June 9, 2009:2129–40crit” versus the “conventional treatment” groups for any
ttained hematocrit, therefore suggesting that increasing
ematocrit is not hazardous in and of itself but rather that
rythropoietin and iron administration in high doses carry
oxic side effects (67). More recently, 2 trials randomized
atients with stages 3 and 4 CKD to partial versus complete
orrection of anemia with erythropoietin (68,69). Although
oth trials failed to show a benefit of achieving normal
oncentrations in this population, the results from Singh
t al. (69) indicated a significantly higher risk of the primary
utcome of death, MI, hospital stay for heart failure, or
troke in the normal hematocrit group, therefore calming
he enthusiasm for the complete correction of anemia in
KD. A recent meta-analysis of all randomized trials has
onfirmed a higher risk of death in patients treated with
igher hemoglobin concentrations in addition to an in-
reased risk of uncontrolled hypertension and arteriovenous
ccess thrombosis (70). Current guidelines endorse the
dministration of erythropoietin for the partial correction of
nemia in CKD with a hemoglobin target of 11 to 12 g/dl
nd not 13 g/dl (71). Several ongoing trials will expand
ur understanding of anemia correction in CKD, including
he TREAT (Trial to Reduce Cardiovascular Events with
ranesp Therapy) study, which is comparing hemoglobin
argets of 13.0 g/dl versus 9.0 g/dl in diabetic patients
ith CKD stage 2 to 4 on a composite outcome of all-cause
ortality and CV morbidity (72).
ardiovascular Imaging in CKD
he presence of endothelial dysfunction, LVH, and volume
nd pressure overload in patients with CKD likely affects
he accuracy of imaging studies in detecting CHD (Online
able 3). Artifacts unique to this group of patients should
e recognized to avoid misinterpretation of the images (73).
he use of contrast agents during coronary angiography and
omputed tomography expose the patients to the risk of
ontrast-induced acute kidney injury, despite strategies for
educing the risk of this complication, a topic that has been
ecently reviewed in the Journal (74). Several studies have
xamined the prognostic information provided by imaging
odalities (Online Table 4). Patients with abnormal stress
yocardial perfusion imaging (MPI) or 2-dimensional
chocardiography have higher event rates than those with
ormal results (75). An abnormal perfusion pattern provides
ore powerful prognostic data than coronary angiography
n the ESRD population (76). In our experience, patients
ith normal stress MPI and CKD have a higher event rate
han that reported in patients without CKD (77). Hakeem
t al. (78) found the annual cardiac death rate to be more
han 3-fold higher in patients with normal MPI and CKD
han in patients with normal MPI and no CKD (2.7% vs.
.8%). The corresponding numbers in patients with abnor-
al MPI were much higher (9.5% and 4%, respectively).
urthermore, there was an inverse correlation between rxtent of perfusion abnormality and GFR (bigger defects in
hose with lower GFR).
Mark et al. (79) found 2 patterns of scarring by magnetic
esonance imaging in patients with ESRD, discrete suben-
ocardial and diffuse. Although both patterns correlated
ith increased LV mass, only subendocardial fibrosis was
ssociated with CHD risk factors, LV systolic dysfunction,
nd severe CHD on angiography. The infrequent and yet
erious complication of nephrogenic systemic fibrosis re-
ated to the use of gadolinium in patients with CKD would
ikely limit its future use (80).
An interesting study by Nishimura et al. (81), using a
ybrid imaging method of perfusion and fatty acid metab-
lism, showed that patients with ESRD and a mismatch
attern (more severe metabolic than perfusion abnormality)
ad worse outcome than patients with normal or matched
efects. This study suggests that subendocardial ischemia is
revalent in patients with CKD (who likely have LVH) and
s prognostically important.
Finally, the high incidence of sudden death in patients
ith CKD suggests that imaging sympathetic innervation of
he heart might provide useful information. In a dog model,
nnervation–perfusion mismatch was predictive of ventric-
lar tachycardia (82). One would hope that nonimaging
redictors of sudden death could be identified, but a recent
tudy in heart failure patients showed that T-wave alternans
id not predict sudden death (83). More recently, we have
hown that patients with ESRD have lower heart rate
esponse to adenosine infusion than patients with normal
enal function, and ESRD patients with a blunted response
ad a higher mortality rate than ESRD patients with a
igher heart rate response (84). The heart rate response to
denosine is thought to be due to sympathetic stimulation.
iabetes mellitus patients also have a blunted heart rate
esponse, most likely due to sympathetic dennervation (85).
LV structural changes are already present in patients with
oderate CKD, and they become more prevalent in ESRD
86,87). The presence of LVH is a strong predictor of
dverse outcomes, independent of conventional risk factors
Online Table 5). LV ejection fraction (EF) is an even more
mportant predictor of outcome in patients with than
ithout CKD (75,88,89). In 1 study, patients with LVEF
40% were twice as likely to die as compared with those
ith normal LVEF even after adjustment for comorbid
onditions (for every 1% decrease in EF the risk of death
ncreased by 2.7%) (Fig. 4) (75).
evascularization in Patients With CKD
atients with CKD are usually excluded from prospective
andomized controlled trials and are often denied coronary
ngiography and PCI for fear of worsening renal function.
he published studies on patients with CKD who undergo
evascularization are usually small, single-centered, and
etrospective.
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June 9, 2009:2129–40 Coronary Heart Disease in Chronic Kidney Diseaseercutaneous coronary revascularization. Multiple stud-
es have evaluated the effect of CKD on short- and long-
erm outcomes after PCI, and these are reviewed in Online
able 6. In general, CKD is a strong predictor of mortality
nd major adverse cardiac events in a dose-dependent
ashion during and after PCI. Despite similar angiographic
uccess rates, procedural and clinical success rates are lower
n patients with CKD, driven by higher incidence of death
nd/or MI, and rates of bleeding and vascular complications
re higher. It is important to note that in many of these
tudies, CKD patients had a higher frequency of risk factors
hat predisposed them to worse outcome, such as left main,
ein graft, or multivessel disease; complex, heavily calcified,
r ostial lesions; acute coronary syndrome presentation;
M, hypertension, prior MI, PCI, or CABG; and acute
enal failure after PCI. The predictive value of GFR for
n-hospital and long-term mortality is irrespective of the
resence or absence of DM. The implantation of newer PCI
evices such as drug-eluting stents has not negated the
etrimental effect of CKD.
Even in acute coronary syndrome CKD is an independent
redictor of in-hospital and long-term mortality after PCI
Online Table 6). In 1 large cohort, mortality rates increased
ncrementally for every 10-ml/min decline in baseline
FR. Contrast-induced acute kidney injury was almost
-fold more common in patients with a baseline GFR
60 ml/min/1.73 m3, and it resulted in relative risks of 13.8
or 30-day mortality and 7.4 for 1-year mortality (90).
The optimal anticoagulation strategy and/or glycoprotein
Ib/IIIa inhibitor to be used in CKD patients is not
ell-defined. In the ESPRIT (Enhanced Suppression of the
latelet IIb/IIIa Receptor with Integrilin Therapy) trial,
KD patients derived a greater magnitude of the treatment
ffect without an increase in bleeding risk (91). In a study of
bciximab during PCI, CKD was associated with increased
leeding risk after PCI in a dose dependent fashion, but the
nteraction between GFR and major bleeding was of bor-
erline statistical significance (odds ratio: 1.18, p  0.06)
Figure 4 Survival by Categories of LVEF
Survival of end-stage renal disease patients evaluated for renal transplantation ac
fraction (LVEF). There is a stepwise increase in mortality for decreasing ejection fr92). In a meta-analysis of 3 randomized trials (n  5,035) romparing bivalirudin with heparin during PCI, adverse
schemic and bleeding events increased with decreasing
FR. Bivalirudin was more effective than heparin in de-
reasing the ischemic and bleeding complications within
ach stratum of renal impairment (93). The GFR and
nemia independently and in combination predicted 30-day
nd 3-year mortality in several large trials that evaluated the
se of abciximab in PCI (94).
Patients with CKD and especially ESRD have higher
n-stent restenosis rates with both bare-metal and drug-
luting stents (Online Table 6). This has been attributed to
igher incidences of DM, diffuse atherosclerosis, and calci-
cations in addition to enhanced oxidative stress and gran-
locyte activation, which increase the risk of in-stent reste-
osis (95,96).
In summary, the use of stents and particularly drug-
luting stents has decreased the rates of in-stent restenosis,
ut these rates remain higher than in patients with normal
enal function. Although ESRD patients have higher rates
f restenosis and major adverse cardiac events, they tend to
erive the most benefit from the use of drug-eluting stents
ompared with bare-metal stents.
urgical revascularization. The same factors that put
KD patients at increased risk of complications with PCI
lso put them at increased risk from CABG. Additionally,
he presence of ascending aortic calcified plaques increases
he operative risk and might require operative modifications
such as use of in situ grafts to avoid aortic manipulations)
97). In patients undergoing CABG, CKD increases bleed-
ng and the risk of blood transfusion, low output syndrome,
nd requirement for post-operative dialysis and prolongs
ntensive care stay (98,99).
A sample of studies evaluating the relationship of ESRD
ith outcome after CABG is reviewed in Online Table 7.
arlier retrospective studies suggested an increased morbid-
ty and mortality in ESRD, and this has now been con-
rmed in larger cohorts. There are some indications that
arly outcomes after CABG in ESRD might have improved
g to categories of left ventricular ejection
Reproduced with permission from Hage et al. (75).cordin
action.ecently. In 1 retrospective multicenter study, the 30-day
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Coronary Heart Disease in Chronic Kidney Disease June 9, 2009:2129–40ortality rates of CABG for ESRD patients decreased from
8% in 1989 to 1993 to 7% in 2000 to 2003, although this
id not translate into improved long-term prognosis (100).
Multiple studies have now shown that even milder forms
f CKD are associated with worse in-hospital and long-
erm outcomes (Online Table 8). When the outcome of
lmost half a million patients who underwent isolated
ABG was examined, operative mortality increased with
eclining GFR, from 1.3% for those with normal renal
unction to 9.3% for patients with severe CKD (101).
mproved early outcomes can be achieved with intensive
erioperative dialysis and improved late outcomes with
xtensive usage of arterial grafts (102,103).
Although ESRD patients have worse outcomes after
ABG than patients with normal GFR, CABG is associ-
ted with improved angina and functional status in patients
ith ESRD (104–106). Similarly, patients with severe
KD experience more improvement in mental health scores
han those without severe CKD, although they might have
orse physical function scores (107).
Off-pump CABG decreases invasiveness and allows
uicker recovery, and because it avoids cardiopulmonary
ypass, it could be useful in patients with CKD who often
ave heavily calcified aortas. Off-pump CABG in CKD and
SRD patients was compared with on-pump CABG in
everal studies and showed comparable early and late out-
omes in most studies (Online Table 9). Despite some
ustified concerns, complete revascularization is possible
ith this strategy, albeit not always achieved, and incom-
lete revascularization in this population has been linked to
ower survival rates. The use of off-pump CABG in patients
ith CKD has been associated with less hematocrit drop
nd blood product use; a lower catabolic rate; fewer dialysis
equirements after surgery; shorter post-operative ventila-
ion time, intensive care unit stay, and hospital stay length;
ower medical cost than on-pump CABG; and in some
eports, even lower mortality.
ercutaneous versus surgical revascularization. Several
tudies compared PCI with surgical revascularization in
KD patients (Online Table 10). Earlier studies showed a
ong-term advantage of CABG compared with balloon
ngioplasty due mainly to higher restenosis rate with angio-
lasty. Survival rates were not significantly different, al-
hough patients who underwent CABG had more extensive
HD. The outcomes of PCI have significantly improved
ith the introduction of newer technologies, although a
omparison between the use of drug-eluting stents and
ABG in patients with CKD has not yet been performed.
evertheless, the short- and long-term outcomes of these
atients remain worse than patients without CKD who
ndergo PCI or CABG.
evascularization versus medical therapy. Few studies
ompared medical therapy with PCI or CABG in CKD
atients (Online Table 11). An analysis from the Duke
atabase showed that CABG was associated with a survival
enefit among patients with both normal renal function and rKD compared with medical management. Compared with
CI, CABG was only associated with survival benefit in
atients with severe CKD (108). Compared with medical
anagement, PCI was associated with a survival benefit
mong patients with normal and mildly and moderately
mpaired renal function but not in patients with severe
KD (108). Another study showed that, compared with
edical therapy, CABG was associated with better survival
n all categories of GFR, whereas PCI was associated with
etter survival in non-CKD and in ESRD patients (109).
he effect of PCI, CABG, or medical therapy alone on the
ong-term survival of patients with CKD presenting with
cute coronary syndrome was studied in 4,758 patients.
hose with severe CKD and not on dialysis had the worst
urvival. Among patients with significant renal dysfunction,
reatment with PCI conferred better survival compared with
ABG or medical therapy (110).
The value of revascularization in asymptomatic patients
ith CKD is less well understood. The ESRD patients who
re evaluated for renal transplantation (RT) undergo rigor-
us evaluation to exclude significant CHD according to the
ccepted guidelines (111). We examined the evaluation of
,698 patients with ESRD considered for RT over a 4-year
eriod. Stress MPI was performed on 60% of these patients,
ue to the presence of risk factors, and coronary angiogra-
hy was performed on only 7%. During the follow-up of
0  15 months, 17% of the patients died. The presence
nd severity of CHD by angiography was not predictive of
urvival, and coronary revascularization did not impact
urvival except in patients with 3-vessel disease. Impor-
antly, of the entire population, 3-vessel disease was present
n only 2% by angiography, thereby limiting the impact of
evascularization on survival in this otherwise high-risk
opulation (75).
T
T is the ultimate treatment for patients with ESRD; RT
esults in better survival and better quality of life at a lower
verall cost than dialysis (112,113). However, CV disease
emains the major cause of death after RT, and RT
ecipients continue to have a higher incidence of fatal and
onfatal CV events than the general population (10).
The effect of traditional CHD risk factors is presumably
imilar in RT recipients and the general population, but RT
ecipients carry a unique baggage of these risk factors.
lthough, at least in theory, the improvement of GFR after
T should favorably affect blood pressure, the prevalence of
ypertension is almost universal in RT recipients (114).
his has been linked to immunosuppressant medications
uch as glucocorticoids and calcineurin inhibitors, and
herefore this excess risk is potentially modifiable with more
odern regimens (115). These same medications (in addi-
ion to sirolimus) have been also associated with dyslipide-
ia, which is prevalent in more than one-half of RTecipients (114). Treatment with statins in a multicenter,
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June 9, 2009:2129–40 Coronary Heart Disease in Chronic Kidney Diseaseandomized, double-blind trial in more than 2,000 RT
ecipients lowered low-density lipoprotein cholesterol and
ecreased cardiac death and nonfatal MI by one-third over
mean follow-up of 5 years, although the primary com-
ined outcome of cardiac death, nonfatal MI, or coronary
evascularization was not different between the treatment
nd the control groups (116). Notably, the use of fluvastatin
n this patient population was demonstrated to be safe, with
ide effect profile and discontinuation rate similar to pla-
ebo. Although this study is in essence a negative study,
ecause the reduction of the primary end point by statin
reatment did not meet statistical significance, the consis-
ency of benefit by treatment across multiple subgroups in
econdary end points (117) and the similarity of benefits of
reatment with statins to other populations combined with
he safety outcome in this population resulted in the wide
ndorsement of this therapy for RT recipients. Clinical
ractice guidelines consider RT recipients to be CHD-risk
quivalent and recommend evaluation for dyslipidemia at
resentation, after any change in status (such as a change in
mmunosuppressive medications) and annually. Treatment
ecommendations otherwise resemble those in the general
opulation and similarly suggest that initial drug therapy
hould be with a statin but emphasize the interaction of
hese medications with immunosuppressive agents (118).
iven the tendency of glucocorticoids and calcineurin
nhibitors to induce hyperglycemia, the high incidence of
ost-transplant DM is not surprising (119). This is com-
ounded by the surprisingly high prevalence of obesity at
he time of RT, with 60% of recipients being overweight or
bese (120). Furthermore, DM has been shown to dramat-
cally increase CHD events as well as mortality after RT,
erhaps even more so than in the general population (119).
Many nontraditional risk factors that exacerbate CV risk
n patients with CKD and ESRD also operate after RT.
enal allograft dysfunction, proteinuria, anemia, chronic
nflammation, hyperhomocysteinemia, hypercoagulation,
nd LVH have all been linked to CHD risk after RT (114).
owever, there are also RT-specific risk factors that have
een linked to events. For example, prolonged dialysis
efore RT has been associated with increased mortality after
ransplantation, perhaps due to the longer exposure to
ialysis-related conditions that accelerate CHD (121). Fur-
hermore, mortality and CHD event rates are higher for
eceased- than living-donor RT (10). A recent analysis has
uggested that these transplant-specific risk factors might in
act interact with the traditional risk factors to modify
ignificantly the risk of CHD events (121).
Aside from affecting risk factors, morbidity, and mortal-
ty, RT also favorably affects LV morphology and function
122,123). A decreased EF in ESRD patients continues to
redict mortality and the occurrence of CV events even after
T (124). Multiple case reports and at least 1 case series
ocuments an improvement in EF after RT. Wali et al.
122) followed 103 patients who underwent RT with an
VEF 40%. After transplantation, 70% had an improvedF, and an EF 50% alone was a significant marker for
ower odds of death or hospital stays.
onclusions
KD is a serious health problem worldwide that leads to
evastating CHD morbidity and mortality. The mecha-
isms that lead to these events are diverse and far more
omplicated than in patients with normal renal function.
HD is uniquely different in CKD from that in the general
opulation, with earlier onset in life, more rapid progres-
ion, a closer association with calcification, increased vascu-
ar stiffness, resistance to statin medications, higher compli-
ations with percutaneous and surgical revascularization,
nd higher rates of sudden death. This review offers a
limpse of the potential mechanisms of increased CHD risk
nd current status of treatment options. If we succeed in
etting our readers interested in this subject, then we have
chieved our goals.
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